An Overlooked Finding in a Recent Acute Severe Ulcerative Colitis Study

A recent study (S Choshen et al. JPGN 2016; 63: 58-64) examined 283 children who were treated with IV steroids for acute severe ulcerative colitis.  This study focused on steroid dosing.  Their conclusion: “there does not seem to be a consistent superiority of high dose (>2 mg/kg/day) versus standard (1.25 mg/kg/day) or low-dose (1 mg/kg/day) methylprednisolone in pediatric acute severe colitis.”

Before looking into the details a little closer, one finding that was not even discussed in the abstract or discussion was the colectomy rate of 31%.  Previous pediatric studies of patients with ulcerative colitis had found rates generally half that rate but notably included patients with milder presentations of ulcerative colitis.  Thus, this rate of 31% (by 1 year after discharge) is useful information to reference when considering pediatric patients with acute severe colitis (ACS).

This study used datasets from the prospective Outcome of Steroid therapy in Colitis Individuals (OSCI) (n=128) and from the retrospective OSCI study (n=99).

Other results:

  • By day 5 of steroids, 45% had at most mild disease (ie PUCAI <35)
  • 31% had failed IV steroids and required salvage therapy (biologic or calcineurin inhibitor)
  • 20% had colectomy by discharge
  • When examining steroid dosage and outcomes, the authors could not discern any differences in need for salvage therapy, PUCAI <35 at day 5, or need for salvage therapy within 1 year. There was a mild difference in length of stay with 9 days in the low-dose group and 10-days in the high dose group.

My take: This large cohort provides some reassurance that current steroid dosing recommendations are probably right, in that there was no discernible improvement with higher doses.  This is in agreement with previous studies in adults which have not shown advantages of methylprednisolone >60 mg/day.  The high colectomy rate of 31% is worth keeping in mind in this population.

Related blog posts:



7 thoughts on “An Overlooked Finding in a Recent Acute Severe Ulcerative Colitis Study

  1. Pingback: Management of Acute Severe Colitis | gutsandgrowth

  2. Pingback: Tofacitinib Case Reports for Acute Severe UC and Pyoderma Gangrenosum | gutsandgrowth

  3. Pingback: “Tofacitinib: A Jak of All Trades” | gutsandgrowth

  4. Pingback: Briefly noted: Mortality in Acute Severe Ulcerative Colitis | gutsandgrowth

  5. Pingback: A Little More Data on Antibiotic Cocktail for Pediatric Acute Severe Ulcerative Colitis | gutsandgrowth

  6. Pingback: Expert Guidance on Inflammatory Bowel Disease (Part 3) | gutsandgrowth

  7. Pingback: Early Assessment of Acute Ulcerative Colitis with ACE (Albumin, CRP, & Endoscopy) | gutsandgrowth

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.